Vontobel Holding Ltd. grew its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 34.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,475 shares of the medical equipment provider's stock after acquiring an additional 10,185 shares during the period. Vontobel Holding Ltd.'s holdings in Hologic were worth $2,438,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in HOLX. EverSource Wealth Advisors LLC boosted its holdings in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co boosted its holdings in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares in the last quarter. Raiffeisen Bank International AG purchased a new stake in Hologic during the fourth quarter worth about $49,000. Finally, West Financial Advisors LLC purchased a new stake in Hologic during the first quarter worth about $50,000. Hedge funds and other institutional investors own 94.73% of the company's stock.
Insider Buying and Selling
In related news, Director Martin D. Madaus purchased 5,445 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.88% of the company's stock.
Hologic Trading Down 0.6%
Shares of NASDAQ:HOLX traded down $0.41 during trading on Monday, reaching $64.37. The stock had a trading volume of 1,789,707 shares, compared to its average volume of 2,376,726. The business has a fifty day moving average price of $60.84 and a 200-day moving average price of $63.60. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The stock has a market cap of $14.34 billion, a P/E ratio of 27.16, a PEG ratio of 2.37 and a beta of 0.55. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the business posted $1.03 earnings per share. The company's revenue was down 1.2% on a year-over-year basis. As a group, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts recently commented on the stock. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Stephens decreased their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Raymond James Financial reissued an "outperform" rating and set a $71.00 price objective (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Finally, Evercore ISI decreased their price objective on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Hologic presently has a consensus rating of "Hold" and an average target price of $77.42.
Check Out Our Latest Stock Report on HOLX
Hologic Company Profile
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
See Also

Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.